169 related articles for article (PubMed ID: 38745123)
21. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
Yang C; Zou K; Zheng L; Xiong B
BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
[TBL] [Abstract][Full Text] [Related]
22. Causal roles and clinical utility of cardiovascular proteins in colorectal cancer risk: a multi-modal study integrating mendelian randomization, expression profiling, and survival analysis.
Tan C; Li Y; Wang K; Lin Y; Chen Y; Zheng X
BMC Med Genomics; 2024 May; 17(1):138. PubMed ID: 38778378
[TBL] [Abstract][Full Text] [Related]
23. Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
Nixon AB; Sibley AB; Liu Y; Hatch AJ; Jiang C; Mulkey F; Starr MD; Brady JC; Niedzwiecki D; Venook AP; Baez-Diaz L; Lenz HJ; O'Neil BH; Innocenti F; Meyerhardt JA; O'Reilly EM; Owzar K; Hurwitz HI
Clin Cancer Res; 2022 Jul; 28(13):2779-2788. PubMed ID: 34965954
[TBL] [Abstract][Full Text] [Related]
24. Large-Scale Genome-Wide Association Study of East Asians Identifies Loci Associated With Risk for Colorectal Cancer.
Lu Y; Kweon SS; Tanikawa C; Jia WH; Xiang YB; Cai Q; Zeng C; Schmit SL; Shin A; Matsuo K; Jee SH; Kim DH; Kim J; Wen W; Shi J; Guo X; Li B; Wang N; Zhang B; Li X; Shin MH; Li HL; Ren Z; Oh JH; Oze I; Ahn YO; Jung KJ; Conti DV; Schumacher FR; Rennert G; Jenkins MA; Campbell PT; Hoffmeister M; Casey G; Gruber SB; Gao J; Gao YT; Pan ZZ; Kamatani Y; Zeng YX; Shu XO; Long J; Matsuda K; Zheng W
Gastroenterology; 2019 Apr; 156(5):1455-1466. PubMed ID: 30529582
[TBL] [Abstract][Full Text] [Related]
25. Mendelian randomization and genetic colocalization infer the effects of the multi-tissue proteome on 211 complex disease-related phenotypes.
Yang C; Fagan AM; Perrin RJ; Rhinn H; Harari O; Cruchaga C
Genome Med; 2022 Dec; 14(1):140. PubMed ID: 36510323
[TBL] [Abstract][Full Text] [Related]
26. Differential genetic influences over colorectal cancer risk and gene expression in large bowel mucosa.
Vaughan-Shaw PG; Timofeeva M; Ooi LY; Svinti V; Grimes G; Smillie C; Blackmur JP; Donnelly K; Theodoratou E; Campbell H; Zgaga L; Din FVN; Farrington SM; Dunlop MG
Int J Cancer; 2021 Sep; 149(5):1100-1108. PubMed ID: 33937989
[TBL] [Abstract][Full Text] [Related]
27. Genetic variation determines VEGF-A plasma levels in cancer patients.
Innocenti F; Jiang C; Sibley AB; Etheridge AS; Hatch AJ; Denning S; Niedzwiecki D; Shterev ID; Lin J; Furukawa Y; Kubo M; Kindler HL; Auman JT; Venook AP; Hurwitz HI; McLeod HL; Ratain MJ; Gordan R; Nixon AB; Owzar K
Sci Rep; 2018 Nov; 8(1):16332. PubMed ID: 30397360
[TBL] [Abstract][Full Text] [Related]
28. Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans.
Winter JM; Curry NL; Gildea DM; Williams KA; Lee M; Hu Y; Crawford NPS
BMC Genomics; 2018 Jun; 19(1):450. PubMed ID: 29890952
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer.
Hyodo I; Doi T; Endo H; Hosokawa Y; Nishikawa Y; Tanimizu M; Jinno K; Kotani Y
Eur J Cancer; 1998 Dec; 34(13):2041-5. PubMed ID: 10070308
[TBL] [Abstract][Full Text] [Related]
30. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array.
Abajo A; Bitarte N; Zarate R; Boni V; Lopez I; Gonzalez-Huarriz M; Rodriguez J; Bandres E; Garcia-Foncillas J
World J Gastroenterol; 2012 Feb; 18(7):637-45. PubMed ID: 22363134
[TBL] [Abstract][Full Text] [Related]
31. The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancer.
Divella R; Daniele A; Abbate I; Bellizzi A; Savino E; Simone G; Giannone G; Giuliani F; Fazio V; Gadaleta-Caldarola G; Gadaleta CD; Lolli I; Sabbà C; Mazzocca A
Cancer Causes Control; 2014 Nov; 25(11):1531-41. PubMed ID: 25135616
[TBL] [Abstract][Full Text] [Related]
32. Associations Between Common and Rare Exonic Genetic Variants and Serum Levels of 20 Cardiovascular-Related Proteins: The Tromsø Study.
Solomon T; Smith EN; Matsui H; Braekkan SK; ; Wilsgaard T; Njølstad I; Mathiesen EB; Hansen JB; Frazer KA
Circ Cardiovasc Genet; 2016 Aug; 9(4):375-83. PubMed ID: 27329291
[TBL] [Abstract][Full Text] [Related]
33. Identification of Common and Rare Genetic Variation Associated With Plasma Protein Levels Using Whole-Exome Sequencing and Mass Spectrometry.
Solomon T; Lapek JD; Jensen SB; Greenwald WW; Hindberg K; Matsui H; Latysheva N; Braekken SK; Gonzalez DJ; Frazer KA; Smith EN; Hansen JB
Circ Genom Precis Med; 2018 Dec; 11(12):e002170. PubMed ID: 30562114
[TBL] [Abstract][Full Text] [Related]
34. Two Novel Long Noncoding RNAs - RP11-296E3.2 and LEF1-AS1can - Separately Serve as Diagnostic and Prognostic Bio-Markers of Metastasis in Colorectal Cancer.
Shi Q; He Y; Zhang X; Li J; Cui G; Zhang X; Wang X
Med Sci Monit; 2019 Sep; 25():7042-7051. PubMed ID: 31536481
[TBL] [Abstract][Full Text] [Related]
35. Risk SNP-Mediated Enhancer-Promoter Interaction Drives Colorectal Cancer through Both
Tian J; Lou J; Cai Y; Rao M; Lu Z; Zhu Y; Zou D; Peng X; Wang H; Zhang M; Niu S; Li Y; Zhong R; Chang J; Miao X
Cancer Res; 2020 May; 80(9):1804-1818. PubMed ID: 32127356
[TBL] [Abstract][Full Text] [Related]
36. Germline genetic regulation of the colorectal tumor immune microenvironment.
Schmit SL; Tsai YY; Bonner JD; Sanz-Pamplona R; Joshi AD; Ugai T; Lindsey SS; Melas M; McDonnell KJ; Idos GE; Walker CP; Qu C; Kast WM; Da Silva DM; Glickman JN; Chan AT; Giannakis M; Nowak JA; Rennert HS; Robins HS; Ogino S; Greenson JK; Moreno V; Rennert G; Gruber SB
BMC Genomics; 2024 Apr; 25(1):409. PubMed ID: 38664626
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide analysis of long non-coding RNA expression and function in colorectal cancer.
Jing F; Jin H; Mao Y; Li Y; Ding Y; Fan C; Chen K
Tumour Biol; 2017 May; 39(5):1010428317703650. PubMed ID: 28468580
[TBL] [Abstract][Full Text] [Related]
38. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.
Varkaris A; Katsiampoura A; Davis JS; Shah N; Lam M; Frias RL; Ivan C; Shimizu M; Morris J; Menter D; Overman M; Tran H; Heymach J; Chun YS; Vauthey JN; Calin G; Kopetz S
Br J Cancer; 2019 Feb; 120(3):340-345. PubMed ID: 30636774
[TBL] [Abstract][Full Text] [Related]
39. Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.
Smith CG; Fisher D; Harris R; Maughan TS; Phipps AI; Richman S; Seymour M; Tomlinson I; Rosmarin D; Kerr D; Chan AT; Peters U; Newcomb PA; Idziaszczyk S; West H; Meade A; Kaplan R; Cheadle JP
Clin Cancer Res; 2015 Aug; 21(15):3453-61. PubMed ID: 25873087
[TBL] [Abstract][Full Text] [Related]
40. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
Hamfjord J; Guren TK; Dajani O; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P; Lingjærde OC; Tveit KM; Kure EH; Pallisgaard N; Spindler KG
Ann Oncol; 2019 Jul; 30(7):1088-1095. PubMed ID: 31046124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
